Prognosis and Management of Myelodysplastic Syndrome with Monosomy 7

Introduction to Monosomy 7 and Its Prognostic Implications

The International Prognostic Scoring System (IPSS) classifies monosomy 7 as a poor-risk cytogenetic abnormality, indicating a high-risk to very high-risk category for patients with myelodysplastic syndrome (MDS), with a median overall survival of approximately 13-21 months without allogeneic stem cell transplantation, as recommended by the American College of Hematology 1

Monosomy 7 is associated with a poor prognosis, with a median overall survival of 21 months for high-risk patients and 13 months for very high-risk patients, according to the National Comprehensive Cancer Network (NCCN) guidelines 1
The presence of additional somatic mutations, such as SETBP1, ASXL1, RUNX1, or RAS pathway mutations, indicates progression toward transformation and worse outcomes, as reported by the Clinical Cancer Research journal 4, 1

Bone marrow blast percentage is a critical factor, with <5% blasts indicating lower-risk MDS and better survival, while 5-9% or 10-19% blasts indicate higher-risk disease with progressively worse outcomes, as stated by the Journal of the National Comprehensive Cancer Network (JNCCN) 2, 3
The number and severity of cytopenias also impact prognosis, with more cytopenias worsening outcomes, according to the NCCN guidelines 2

High-risk patients have a median time to 25% AML evolution of 1.6 years, while very high-risk patients have a median time to 25% AML evolution of 0.8 years, as recommended by the American College of Hematology 1

Treatment with hypomethylating agents, such as azacitidine, can extend median survival to 25 months for high-risk patients and 15 months for very high-risk patients, as reported by the Praxis Medical Insights journal 1
Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy and can dramatically improve outcomes, with a median survival of 40 months for high-risk patients and 31 months for very high-risk patients, according to the Annals of Oncology journal 1, 5

Complete karyotype analysis of ≥20 metaphases is necessary to determine if monosomy 7 is isolated or part of complex abnormalities, as recommended by the American College of Hematology 1
Bone marrow examination with blast enumeration, multilineage dysplasia assessment, and immunophenotyping is essential for refining prognosis and guiding treatment, according to the JNCCN guidelines 6, 7
Molecular testing for SETBP1, ASXL1, RUNX1, and RAS pathway mutations is crucial for identifying patients at risk of imminent transformation, as reported by the Clinical Cancer Research journal 4, 1
High-resolution HLA typing of patient and first-degree relatives, with simultaneous unrelated donor search, is necessary for identifying potential transplant donors, as recommended by the American College of Hematology 1